Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cytovir ADV
- Development stage
- Phase 2
- Lead developer
- Kuur Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Cytovir ADV is an investigational cell therapy designed for the treatment of adenovirus infections in patients following allogeneic hematopoietic stem cell (bone marrow) transplantation. The therapy consists of naturally occurring T lymphocyte cells (T cells) derived from the bone marrow donor, which are specific for adenovirus antigens. These T cells are intended to transfer adenovirus immunity from the donor to immunocompromised transplant recipients, who are at high risk for life-threatening adenoviral infections due to prolonged immune suppression post-transplant. Cytovir ADV is being evaluated in clinical trials, such as the ASPIRE Phase I/II trial at Great Ormond Street Hospital in London, to assess its safety and efficacy in reconstituting immediate and long-lasting immunity against adenovirus[2][4]. The product meets criteria as an advanced therapy medicinal product (ATMP), specifically as an advanced therapy investigational medicinal product.
- Brand names
- Cytovir-ADV
- Other names
- Adenovirus-specific T-cellsADV-specific T-cellsADV-VST
02
Targets
Adv-pMHC-I (Adenovirus-derived peptide–HLA class I complex)
Beyond the preview
Go deeper on Cytovir ADV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytovir ADV.